A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease (INVOKE-2)

  • End date
    Jan 8, 2024
  • participants needed
  • sponsor
    Alector Inc.
Updated on 14 September 2022
mini-mental state examination
alzheimer's disease


A phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in participants with Early Alzheimer's Disease.


This is a phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 administered intravenously in participants with Early Alzheimer's Disease.

Link for more information:

Condition Alzheimer's Disease
Treatment Placebo, AL002
Clinical Study IdentifierNCT04592874
SponsorAlector Inc.
Last Modified on14 September 2022


Yes No Not Sure

Inclusion Criteria

Diagnosis of Early AD including evidence of brain amyloidosis by CSF or PET
MMSE score ≥ 22 points, CDR Global Score of 0.5 - 1.0, and RBANS score on the DMI ≤85
Study partner who consents to study participation and who cares for/visits the participant at least 10 hours a week
Written informed consent must be obtained and documented (from the participant or, where jurisdictions allow it, from their legal decision maker)

Exclusion Criteria

Dementia due to a condition other than AD including, but not limited to, FTD, Parkinson's disease, dementia with Lewy bodies, Huntington disease, or vascular dementia
Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins
Current uncontrolled hypertension, diabetes mellitus or thyroid disease. Clinically significant heart disease, liver disease or kidney disease
History or evidence of clinically significant brain disease other than AD
Females who are pregnant or breastfeeding, or planning to conceive within the study period
Any experimental vaccine or gene therapy
History of unresolved cancer
Current use of anticoagulant medications
Residence in a skilled nursing facility, convalescent home, or long term care facility at screening; or requires continuous nursing care
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note